To assess the diagnostic value of these biomarkers and understand whether they could predict the severity of pulmonary disease in COVID-19 patients, plasma levels of SP-D, MMP8 and KL-6 were measured in the ARDS and non-ARDS groups. This evidence concerns the gene MUC1 and lung disorder.